Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TP63

TP63

Basics

Aliases:
This biomarker is also known as:
  • p51,
  • Keratinocyte transcription factor KET,
  • OFC8,
  • tumor protein 63,
  • tumor protein p63,
  • SHFM4,
  • p63,
  • tumor protein p53-like,
  • EEC3,
  • p40,
  • P73H,
  • p73H,
  • P73L,
  • tumor protein p63 deltaN isoform delta,
  • KET,
  • AIS,
  • LMS,
  • Transformation-related protein 63,
  • Chronic ulcerative stomatitis protein,
  • RHS,
  • CUSP,
  • tumor protein p53-competing protein,
  • P63,
  • p73L,
  • TP73L,
  • p53CP,
  • TP53L,
  • B(p51A),
  • B(p51B),
  • amplified in squamous cell carcinoma,
  • Tumor protein p73-like,
  • NBP,

View in BioMuta

Description…

TP63 is a member of the p53 family of transcription factors. It acts as a sequence specific DNA binding transcriptional activator or repressor. Many transcripts encoding different proteins have been reported but the biological validity and the full-length nature of these variants have not been determined. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. TP63 may be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. It is involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis.

Attributes

QA State: Under Review
Type: Gene
Short Name:
HGNC Name: TP63

Datasets

There are no datasets associated with this biomarker.

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Resources

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.